CN103974716B - 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 - Google Patents

凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 Download PDF

Info

Publication number
CN103974716B
CN103974716B CN201280060378.XA CN201280060378A CN103974716B CN 103974716 B CN103974716 B CN 103974716B CN 201280060378 A CN201280060378 A CN 201280060378A CN 103974716 B CN103974716 B CN 103974716B
Authority
CN
China
Prior art keywords
facvii
facviia
derivative
complex
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280060378.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN103974716A (zh
Inventor
金大振
李炳善
洪性焕
许容豪
郑圣烨
权世昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of CN103974716A publication Critical patent/CN103974716A/zh
Application granted granted Critical
Publication of CN103974716B publication Critical patent/CN103974716B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201280060378.XA 2011-10-06 2012-10-05 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 Expired - Fee Related CN103974716B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110102099 2011-10-06
KR10-2011-0102099 2011-10-06
PCT/KR2012/008102 WO2013051900A2 (en) 2011-10-06 2012-10-05 Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof

Publications (2)

Publication Number Publication Date
CN103974716A CN103974716A (zh) 2014-08-06
CN103974716B true CN103974716B (zh) 2016-08-24

Family

ID=48044320

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280060378.XA Expired - Fee Related CN103974716B (zh) 2011-10-06 2012-10-05 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途

Country Status (18)

Country Link
US (1) US9597378B2 (enExample)
EP (2) EP2763693A4 (enExample)
JP (1) JP6108630B2 (enExample)
KR (1) KR20130037659A (enExample)
CN (1) CN103974716B (enExample)
AR (1) AR088267A1 (enExample)
AU (1) AU2012319308B2 (enExample)
BR (1) BR112014008224A2 (enExample)
CA (1) CA2851223A1 (enExample)
IL (1) IL231930A0 (enExample)
MX (1) MX354493B (enExample)
MY (1) MY168754A (enExample)
PH (1) PH12014500735A1 (enExample)
RU (1) RU2620072C2 (enExample)
SG (1) SG11201401205UA (enExample)
TW (1) TWI565715B (enExample)
WO (1) WO2013051900A2 (enExample)
ZA (1) ZA201402745B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN103599527A (zh) * 2013-08-16 2014-02-26 安源生物科技(上海)有限公司 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
DK3127923T3 (da) * 2014-03-31 2021-11-22 Hanmi Pharm Ind Co Ltd Fremgangsmåde til forbedring af oppløselighed af protein og peptid ved hjælp af immunoglobulin-fc-fragment-binding
EP3373926B1 (en) 2015-11-10 2020-06-10 Sun Chemical Corporation Alkoxylated dispersing agents
KR102041671B1 (ko) * 2017-05-08 2019-11-28 가톨릭대학교 산학협력단 β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
WO2019240881A2 (en) * 2018-04-23 2019-12-19 Emory University Vip and vip agonists, nanoparticles, and uses in inflammatory t-cell mediated disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723219A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 利用免疫球蛋白片段的蛋白质复合物及其制备方法
US20060258851A1 (en) * 2003-10-07 2006-11-16 Novo Nordisk Healthcare A/G Hybird molecules having factor VII/VIIa activity
US20080260755A1 (en) * 2006-06-14 2008-10-23 Hubert Metzner Proteolytically cleavable fusion proteins with high molar specific activity
US20090298760A1 (en) * 2006-02-06 2009-12-03 Thomas Weimer Modified Coagulation Factor VIIa With Extended Half-Life

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2434032T3 (es) * 2005-06-17 2013-12-13 Novo Nordisk Health Care Ag Compuestos de FVIIA diméricos y multiméricos
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
KR101104684B1 (ko) 2008-12-02 2012-01-16 이화여자대학교 산학협력단 관찰 방향 및 조명을 고려한 피부 질감 렌더링 방법 및 그 장치
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258851A1 (en) * 2003-10-07 2006-11-16 Novo Nordisk Healthcare A/G Hybird molecules having factor VII/VIIa activity
CN1723219A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 利用免疫球蛋白片段的蛋白质复合物及其制备方法
US20090298760A1 (en) * 2006-02-06 2009-12-03 Thomas Weimer Modified Coagulation Factor VIIa With Extended Half-Life
US20080260755A1 (en) * 2006-06-14 2008-10-23 Hubert Metzner Proteolytically cleavable fusion proteins with high molar specific activity

Also Published As

Publication number Publication date
MX354493B (es) 2018-03-08
BR112014008224A2 (pt) 2017-04-11
SG11201401205UA (en) 2014-05-29
WO2013051900A2 (en) 2013-04-11
TWI565715B (zh) 2017-01-11
PH12014500735A1 (en) 2022-05-11
MY168754A (en) 2018-11-30
AU2012319308B2 (en) 2017-08-31
AR088267A1 (es) 2014-05-21
EP3417881A1 (en) 2018-12-26
MX2014004099A (es) 2014-05-21
AU2012319308A1 (en) 2014-05-01
EP2763693A2 (en) 2014-08-13
ZA201402745B (en) 2016-04-27
JP2014530018A (ja) 2014-11-17
CA2851223A1 (en) 2013-04-11
NZ623726A (en) 2016-06-24
US20140271607A1 (en) 2014-09-18
IL231930A0 (en) 2014-05-28
KR20130037659A (ko) 2013-04-16
RU2014115291A (ru) 2015-11-20
RU2620072C2 (ru) 2017-05-22
CN103974716A (zh) 2014-08-06
JP6108630B2 (ja) 2017-04-05
EP2763693A4 (en) 2015-12-09
US9597378B2 (en) 2017-03-21
TW201331223A (zh) 2013-08-01
WO2013051900A3 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CN103974716B (zh) 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途
JP5726404B2 (ja) 半減期が延長された改変凝固第ＶＩＩａ因子
TWI710570B (zh) 用於治療代謝異常之組成物及方法
JP2008509688A (ja) 改変ビタミンｋ依存性ポリペプチド
HK1207591A1 (en) Chimeric clotting factors
CA2649199C (en) Method of increasing the in vivo recovery of therapeutic polypeptides
CN104774269B (zh) 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
JP2022118184A (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
JP2017521070A (ja) 改変フォンウィルブランド因子
TWI443106B (zh) 使用免疫球蛋白片段之ＶＩＩａ因子錯合物
JP6181158B2 (ja) ＴＮＦ−α阻害剤としてのＴＡＣＥプロドメインの変異体およびその医学的使用
HK1196565B (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
HK1196565A (en) Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
NZ623726B2 (en) Blood coagulation factor ? and ?a derivatives, conjugates and complexes comprising the same, and use thereof
AU2013202563A1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
HK1129421B (en) Modified coagulation factor vila with extended half-life

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1196565

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1196565

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160824

Termination date: 20191005